Emcure Share Price in Focus; Subsidiary Gennova to Sell mRNA Business to Immunoscript for ₹139.5 Crore

Emcure Pharmaceuticals has announced that its subsidiary, Gennova Biopharmaceuticals Limited, has entered into a Business Transfer Agreement (BTA) to divest its mRNA business to Immunoscript Life Science Private Limited. 

The transaction will be executed as a going concern on a slump sale basis for a lump sum cash consideration of ₹1,395 million (₹139.5 crore). The agreement was signed on 10 July 2026.  

Strategic Portfolio Realignment 

The proposed sale is part of Gennova's broader strategy to reorganise its business operations and concentrate on its core biotechnology businesses. 

Following the divestment, the company will continue focusing on research and development, manufacturing and marketing of biotechnology-based products, including biosimilars and adjacent therapeutic platforms. During FY2025-26, Gennova reported a turnover of ₹4,917.42 million.  

Business Contribution 

The mRNA division generated revenue of ₹647.10 million in FY2025-26, contributing 0.71% of Emcure's consolidated revenue of ₹91,158.88 million. 

The business also had a net worth of ₹1,326.31 million, representing 2.68% of Emcure's consolidated net worth of ₹49,500.32 million. The transaction is expected to be completed by 17 July 2026, subject to the terms of the agreement and other required approvals.  

Buyer and Transaction Details 

The buyer, Immunoscript Life Science Private Limited, is a Pune-based company promoted by Dr. Sanjay Singh, formerly a director of Gennova. 

The company is focused on precision immunology, combining biological engineering, artificial intelligence and scalable biomanufacturing to develop next-generation vaccines and advanced therapeutics. Immunoscript was incorporated in April 2026 and is not part of Emcure's promoter or group companies.  

Read More: Aurobindo Pharma Share Price in Focus as it Incorporates PT Auro Pharm Indonesia for Manufacturing Operations! 

Emcure Pharmaceuticals Share Price Performance  

As of 10 July 2026, Emcure Pharmaceuticals share price closed at ₹1,805 per share, reflecting a decline of 0.25% from the previous trading session. 

Conclusion 

The transaction reflects Gennova's focus on streamlining its business portfolio while sharpening its emphasis on core biotechnology segments. The sale also marks the transfer of its mRNA business to a company focused on precision immunology and advanced therapeutic development.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.